The present results describe a potentially new proteolytic mechanism arising from inflammation to transform ANGPT2 into a Tie2 antagonist and a new action of a clinical-stage compound to mitigate adverse outcomes of sepsis in a CATK- and ANGPT2-dependent fashion. Here, TEK is linked to Sepsis.